Thesis

Candel Therapeutics' stock at $5.10 implies roughly 12-16% probability that CAN-2409 (aglatimagene besadenovec) gets FDA approval for localized prostate cancer. The drug met its SPA-agreed primary endpoint in a 745-patient Phase 3 trial (DFS HR 0.70, p=0.0155). It holds triple FDA designation: SPA, RMAT, and Fast Track. RTW Investments — an $800M+ healthcare fund with a proven track record in contingent royalty deals — committed $100M payable on approval. A director bought $3M at the FPO price three weeks ago.

Historical base rate for SPA-compliant Phase 3 trials that meet primary endpoints with clean methodology: 40-60%+ approval. We estimate 45%. That 30-point gap between market-implied and evidence-based approval probability is the entire thesis.

This is not a discovery play (Phase 3 results are public), a magnitude play (analysts have $18 targets), or a timing play (catalysts are announced). It is a probability mispricing play — the market is systematically underpricing FDA approval odds because of biotech winter sentiment, a broken FPO, and 21% short interest momentum.

The Clinical Data

Phase 3 was clean. 745 patients, randomized, double-blind, placebo-controlled, across 60+ sites. Disease-free survival primary endpoint met with HR 0.70 (95% CI 0.52-0.94, p=0.0155). Well tolerated — no increase in serious adverse events versus placebo. FDA agreed to the trial design in advance under a Special Protocol Assessment.

ASTRO September 2025 subgroup data showed consistent benefit across ALL prostate cancer risk categories. Hazard ratios ranged from 0.49 (intermediate-risk favorable) to 0.69 (high-risk disease). Moderate hypofractionated EBRT subgroup: HR 0.52 (CI 0.30-0.93). Conventional EBRT subgroup: HR 0.76 (CI 0.53-1.07) — this one crosses 1.0.

The conventional EBRT subgroup is the only bear talking point in the clinical data. It doesn't hold up. FDA precedent is clear: CHECKMATE-057 (nivolumab) had a PD-L1 <1% subgroup HR 0.90 (CI 0.66-1.24) — approved. KEYNOTE-042 (pembrolizumab) had a TPS 1-49% subgroup HR 0.92 (CI 0.77-1.11) — approved. SOPHIA (margetuximab) had a subgroup that actually FAVORED the control arm (HR 1.78) — still approved, because the subgroup was underpowered with no mechanistic basis for heterogeneity. FDA's stated principle: subgroups "lack adequate sample size for rigorous statistical inference." CAN-2409's conventional EBRT subgroup still favors treatment — it's directionally positive, just underpowered. There is no biological reason aglatimagene would work differently depending on radiation delivery method.

The one SPA failure worth examining is MDMA/Lykos in 2024. That drug met its SPA endpoints but was rejected — for data integrity concerns, bias in efficacy data, and missing safety information. Statistical failure was not the issue. CAN-2409's trial has none of those problems. If CADL's BLA gets rejected, it won't be because the Phase 3 statistics were insufficient. It'll be CMC, manufacturing, or something we can't see in the filing.

Extended follow-up data — including time to metastasis — is expected Q2 2026. This is the next de-risking catalyst. Time to metastasis is a harder endpoint than DFS. If positive, the BLA package strengthens materially and P(approval) upgrades to 55-60%. If null, the thesis weakens but doesn't die — DFS is the SPA-agreed endpoint, not metastasis.

The RTW Deal

On February 19, 2026, RTW Investments signed a Purchase Agreement committing $100M to Candel upon FDA approval. In exchange, RTW gets a tiered royalty on US net sales: 4.67% on the first $1B annually, 1.33% above that, capped at $250M total. The deal is contingent — zero cash until approval.

This is not a one-off. RTW runs a dedicated royalty sub-portfolio within their $800M+ fund. Three confirmed precedents:

Mavacamten (Cytokinetics, 2020). RTW acquired a royalty interest in the heart drug. FDA approved. RTW returned >3x, contributing +4.9% to NAV. Sold to Bristol Myers Squibb in April 2022.

AQST Anaphylm (August 2025). RTW committed $75M contingent on FDA approval of an epinephrine sublingual film. Nearly identical structure: tiered revenue share, contingent on approval, capped at $187.5M. AQST received a Complete Response Letter. RTW's response: extended the marketing approval deadline to June 2027, committed an additional $5M equity purchase, and took warrants at $4.00/share. They doubled down on the setback. That's conviction, not speculation.

CADL CAN-2409 (February 2026). $100M — larger than the AQST deal despite CADL being earlier stage (no BLA filed yet, versus AQST which had a filed NDA). This is revealed preference. RTW either sees higher approval probability, a larger commercial opportunity, or both.

Director Paul Manning purchased $3M of stock at the FPO price ($5.45) on the open market in February 2026. Form 4, P-code — a genuine purchase, not options or RSU vesting. He's underwater by ≈6% as the stock sits at $5.10. Directors don't buy $3M of stock in companies they expect to fail.

The Competitive Void

No new pharmacologic therapy has been approved for localized prostate cancer in approximately 20 years. We corroborated this claim. Xtandi ($5.59B revenue, 2025) and Erleada ($2.4B revenue, 2023) target metastatic or castration-resistant disease — a completely different patient population treated by different specialists. Neither is approved for newly diagnosed localized intermediate-to-high-risk prostate cancer. CAN-2409 treats the localized setting: radiation oncologists, not medical oncologists.

The nearest pipeline competitor is Alessa Therapeutics (enzalutamide implant for localized prostate cancer). Phase 1. First-in-man. Up to 20 patients. Private company, $15M seed financing. Years behind CAN-2409. The next closest is the ATLAS trial (apalutamide + ADT, peri-operative in high-risk localized) — an existing drug in a new setting, not a novel mechanism.

CAN-2409 would be only the second oncolytic virus/gene therapy ever approved by the FDA. The first was Amgen's Imlygic (T-VEC) for melanoma in 2015. No competitor is close to filing for oncolytic virus therapy in prostate cancer.

We searched 5,465 earnings call transcripts for mentions of CAN-2409, Candel, aglatimagene, or oncolytic virus prostate cancer. Zero results. Big pharma is not talking about this space. That reads both ways — no competition, but also possibly no interest. Given that prostate cancer is an $8B+ drug market, the more likely explanation is that big pharma is focused on advanced/metastatic disease and hasn't noticed the localized opportunity.

Factor Decomposition

Standard factor regression is misleading here. CADL has a -0.90 beta (negative — moves inversely to market), 64.4% idiosyncratic volatility, and has declined 37% over the past year while XBI rose 45.6%. The negative beta reflects anti-correlation with risk-on sentiment during biotech winter, not structural market sensitivity. For a binary-catalyst biotech, daily covariance with SPY is noise.

The real decomposition is catalyst-driven. Six factors, three with edge:

Factors 1-3 are partially correlated — they're different lenses on the same question: does this drug get approved? The independent information content is: (a) the clinical data itself, (b) RTW's incremental diligence beyond public data, and (c) our regulatory precedent interpretation. Don't triple-count.

The thesis reduces to one bet: is P(approval) closer to 12-16% (market) or 45% (our estimate)?

The Bear Case We Can't See

What would justify 10-15% implied approval on an SPA-compliant Phase 3 that met its endpoint with clean methodology? Four possibilities:

1. CMC/manufacturing issues. Not disclosed in the filing. Process validation (four large-scale batches) is expected Q2 2026. If it fails, BLA delays regardless of clinical data. This is the primary blind spot — we cannot assess manufacturing readiness from SEC filings.

2. FDA private feedback. The triple designation (SPA + RMAT + Fast Track) suggests FDA engagement, but pre-BLA meeting details aren't disclosed. If FDA privately signaled concerns, we wouldn't know.

3. DFS without metastasis benefit is insufficient. Q2 2026 data will clarify. DFS is the SPA-agreed endpoint, so this shouldn't be a showstopper — but a null metastasis result would weaken the BLA package.

4. Market is pricing commercial risk, not approval risk. A $400M market cap biotech trying to commercialize in a major disease area, with a pending patent and 12-year biologics exclusivity as primary IP protection. If the market is conflating commercial execution risk with approval probability, that's a pricing error in our favor — approval and commercialization are independent questions.

We can address #3 in Q2. We can't address #1 or #2 from public data. #4 would be market error.

Financials and Cash

Cash at December 31, 2025: $119.7M. Plus FPO net proceeds (February 2026): $93.5M. Total: approximately $213M. Company guides runway to Q1 2028.

FY2025 operating cash burn: $38.3M, up 42% from $27.0M in FY2024. Clinical development costs rose 183% year-over-year — driven by manufacturing and regulatory costs for BLA preparation. Commercial readiness spending appeared for the first time: $2.7M in 2025 (zero in 2024). Total operating expenses: $48.3M (up 44.6% YoY).

Burn will accelerate in 2026-2027. BLA preparation costs peak around submission. Pre-launch activities ramp. Realistic 2026 burn: $50-65M. At $65M/year, $213M lasts to mid-2028 — still past the H2 2027 PDUFA date. Tight but survivable.

Trinity Capital term loan: $130M facility, $50M drawn at close (October 2025). Interest rate 9.75%+ floating. First lien on all assets. Interest-only for first 36 months. 4.25% exit fee. Expensive capital, but provides non-dilutive bridge if needed.

No going concern flag. KPMG clean audit opinion.

Post-FPO shares outstanding: 73.2M. Fully diluted including warrants: ≈80.8M. At $5.10, market cap ≈$374M. Enterprise value ≈$161M. That $161M is what the market assigns to the entire pipeline.

Entry and Forward EV

Scenario-weighted expected value (18 months):

EV $9.70 versus current $5.10 = +90% expected return over 18 months. Annualized alpha after edge (80%) and conviction (65%) adjustments: ≈28%.

The sensitivity table is the whole thesis:

At market-implied 15%, the stock is roughly fairly valued. The entire edge comes from believing P(approval) exceeds 20%. At 25%, positive EV emerges. At 35%, it's compelling. At 45%, the risk/reward is 1:2.2 on a probability-weighted basis.

Options market split: Near-term puts dominate (March P/C OI 3.31 — bears pressing the broken FPO). But July P/C OI is 0.06 — calls are 17.8x puts. October P/C OI is 0.16 — calls are 6.3x puts. Someone is positioned for the Q2 data catalyst and BLA filing. $12 strike July calls (154 OI at $0.30) imply informed speculation on a violent re-rating from Q2 data.

Timing: Three windows. (1) Now to Q2 data — buy the apathy at $5.10, oversold, before catalyst. Retail edge: being early. (2) After Q2 data — buy confirmation at $7-8. Institutional playbook, not retail edge. (3) After BLA filing — no edge, just riding the coin flip. Window 1 is the only one where edge exists at this price.

Risk management: Size for survival at the $3.00 bear case (-41%). This is a binary outcome where Paleologo proportional sizing is less appropriate than Kelly. Hard stop below $4.00 — if the 52-week low breaks, something we can't see is wrong.

What Changes the Picture

Bullish catalysts (watch for):

• Q2 2026: Time-to-metastasis data positive (upgrades P(approval) to 55-60%)
• Q2 2026: Process validation completed (removes CMC blind spot)
• Any point: Big pharma mentions CAN-2409 on earnings call (M&A enters conversation)
• Any point: Short covering begins (10.8 days to cover = multi-week squeeze)
• Any point: Additional insider buying below $5

Bearish signals (watch for):

• Q2 2026: Time-to-metastasis data null (weakens BLA package)
• Any 8-K: Manufacturing delays or BLA timeline change
• Any point: RTW amendment or covenant change (echoes AQST CRL)
• Quarterly: Burn rate exceeding $17M/quarter (threatens runway before PDUFA)

Conclusion

The market is pricing CADL for failure. The evidence says otherwise. An SPA-compliant Phase 3 met its primary endpoint with clean methodology, consistent subgroup data, and no safety concerns. RTW committed $100M on the same bet — from a fund that returned >3x on the same deal structure with mavacamten. No new drug has been approved for localized prostate cancer in 20 years. Nobody is competing.

The gap between market-implied approval probability (≈12-16%) and evidence-based estimate (≈45%) is wide enough to drive a truck through. The question is whether we're missing something the market sees — CMC issues, private FDA feedback, or something not in the filing. Q2 2026 time-to-metastasis data is the next decision point. If positive, the thesis strengthens and the re-rating begins. If null, reassess. If negative, walk away.

At $5.10 with $213M in cash, the market is paying $161M for a drug that met its SPA Phase 3 endpoint in an uncontested therapeutic area with triple FDA designation and $100M in contingent smart money behind it. Either the market is right and we're missing something material, or it's a 30-point probability mispricing in a small-cap biotech that nobody is watching.

We think it's the latter.

LR: 2.2 — Strong bullish divergence. Market is underpricing approval probability. Evidence quality is high (10-K filing, Phase 3 data, regulatory precedents, cross-ticker RTW corroboration). Discounted from 2.5 because: binary outcome, CMC blind spot, and we genuinely cannot explain why 21% of the float is short.

Evidence